Adocia’s clinical pipeline includes four novel insulin formulations for prandial treatment of diabetes and also includes an aqueous formulation of human glucagon. Adocia preclinical pipeline includes three products and recently added a fourth program, a preclinical stage cell therapy initiative focused on development of a hydrogel scaffold for use in people with type 1 diabetes.
Insulin and insulin analogs are our main focus and area of expertise. Our products are innovative formulations of blockbuster insulins that improve and facilitate patients’ insulin therapy. This portfolio of insulins is an opportunity both for established companies in the diabetes field or for newcomers entering the insulin market.
- BioChaperone® Lispro a more physiological short-acting insulin for better outcomes.
- BioChaperone® Combo which delivers a fast-acting insulin analog and long-acting insulin glargine in a single injection.
- M1 Pram the first co-formulation of prandial insulin and pramlintide. It would meet the pressing medical need for tight postprandial glycemic control and lower glycemic variability without adding an additional product and more injections.
- BioChaperone® glucagon: Using the BioChaperone® technology, Adocia aims to develop a stable aqueous solution of recombinant human glucagon, that may be used in varied settings, including the treatment of severe hypoglycaemia and the use in an artificial pancreas.
Adocia is looking for patient-oriented partners who share our culture in innovation, and may bring complementary expertise in:
- Medical Science and Medical Practice.
- Late-stage clinical development.
- Regulatory Affairs.
- Marketing and commercialization.
For more information on the collaboration opportunities with Adocia, please contact Adocia’s Business Development.